產(chǎn)品詳情
簡(jiǎn)單介紹：
重組人Neuroserpin蛋白與其它公司提供的重組蛋白不同，rHuNeuroserpin蛋白產(chǎn)品為采用CFS的無(wú)細(xì)胞麥胚蛋白合成系統(tǒng)表達(dá)出來(lái)的重組蛋白，可表達(dá)出對(duì)細(xì)胞有毒性、易被蛋白酶降解的蛋白；并獲得具有良好的可溶性，并有翻譯后修飾、從而部分具有功能的蛋白.同時(shí)獨(dú)有的全自動(dòng)蛋白純化技術(shù)則簡(jiǎn)便高效，將蛋白純化過(guò)程中對(duì)蛋白的損傷降低到*小程度.重組人Neuroserpin蛋白（全長(zhǎng)序列）產(chǎn)品可用于Western Blot驗(yàn)證、抗體制備、蛋白檢測(cè)、ELISA等試驗(yàn)中.
詳情介紹：
重組人Neuroserpin蛋白
| Synonyms | Peptidase Inhibitor 12, PI-12, Serpin I1, NSP |
| Species | Human |
| Accession | Q99574 |
| GeneID | 5274 |
| Source | Escherichia coli. |
| Molecular Weight | 重組人Neuroserpin蛋白Approximately 44.7 kDa, a single non-glycosylated polypeptide chain containing 394 amino acid residues. |
| Quantity | 5μg/25μg/1000μg |
| AA Sequence | 重組人Neuroserpin蛋白TGATFPEEAI ADLSVNMYNR LRATGEDENI LFSPLSIALA MGMMELGAQG STQKEIRHSM GYDSLKNGEE FSFLKEFSNM VTAKESQYVM KIANSLFVQN GFHVNEEFLQ MMKKYFNAAV NHVDFSQNVA VANYINKWVE NNTNNLVKDL VSPRDFDAAT YLALINAVYF KGNWKSQFRP ENTRTFSFTK DDESEVQIPM MYQQGEFYYG EFSDGSNEAG GIYQVLEIPY EGDEISMMLV LSRQEVPLAT LEPLVKAQLV EEWANSVKKQ KVEVYLPRFT VEQEIDLKDV LKALGITEIF IKDANLTGLS DNKEIFLSKA IHKSFLEVNE EGSEAAAVSG MIAISRMAVL YPQVIVDHPF FFLIRNRRTG TILFMGRVMH PETMNTSGHD FEEL |
| Purity | > 95 % by SDS-PAGE and HPLC analyses. |
| Biological Activity | 重組人Neuroserpin蛋白Fully biologically active when compared to standard. The ED50 as determined by a cell proliferation assay using rat C6 cells is less than 0.5 μg/ml, corresponding to a specific activity of > 2000 IU/mg. |
| Physical Appearance | Sterile Filtered White lyophilized (freeze-dried) powder. |
| Formulation | Lyophilized from a 0.2 μm filtered concentrated solution in PBS, pH 7.4. |
| Endotoxin | Less than 1 EU/μg of rHuNeuroserpin as determined by LAL method. |
| Reconstitution | We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute in sterile distilled water or aqueous buffer containing 0.1 % BSA to a concentration of 0.1-1.0 mg/mL. Stock solutions should be apportioned into working aliquots and stored at ≤ -20 °C. Further dilutions should be made in appropriate buffered solutions. |
| Storage | This lyophilized preparation is stable at 2-8 °C, but should be kept at -20 °C for long term storage, preferably desiccated. Upon reconstitution, the preparation is stable for up to one week at 2-8 °C. For maximal stability, apportion the reconstituted preparation into working aliquots and store at -20 °C to -70 °C. Avoid repeated freeze/thaw cycles. |
| 重組人Neuroserpin蛋白 | |
| Reference |
1. Berger P, Kozlov SV, Cinelli P, et al. 1999. Mol Cell Neurosci, 14: 455-67. 2. Hill RM, Coates LC, Parmar PK, et al. 2002. Ann N Y Acad Sci, 971: 406-15. 3. Simonin Y, Charron Y, Sonderegger P, et al. 2006. J Neurosci, 26: 10614-9. 4. Ricagno S, Caccia S, Sorrentino G, et al. 2009. J Mol Biol, 388: 109-21. 5. Yepes MandLawrence DA. 2004. Thromb Haemost, 91: 457-64. |
| Background | Neuroserpin encoded by the SERPINI1 gene in humans is a member of the serine proteinase inhibitor (serpin) family. It reacts preferentially with tissue-type plasminogen activator (tPA). Neuroserpin is expressed mainly in the central nervous system (CNS) in response to neuronal depolarization and plays an important role in the development of synaptic plasticity. Mutations in human neuroserpin result in a form of autosomal dominant inherited dementia which is characterized by the presence of intraneuronal inclusion bodies and is known as Familial Encephalopathy with Neuroserpin Inclusion Bodies. |
